Homebiotech

biotech

Axsome (AXSM) Gains as Alzheimer’s Agitation Study Meets Goal

Axsome (AXSM) Gains as Alzheimer’s Agitation Study Meets Goal

November 29, 2022

Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?

Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?

November 29, 2022

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

November 29, 2022

Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split

Cidara Therapeutics Announces Two Leading Independent Proxy Advisory Firms Recommend Stockholders Vote “FOR” Proposed Reverse Stock Split

November 29, 2022

Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation

Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation

November 29, 2022

Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund

Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund

November 29, 2022

Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders

Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders

November 29, 2022

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

November 29, 2022

Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia

Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia

November 29, 2022

Investors who lost Money with shares of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) should contact the Shareholders Foundation in connection with the Lawsuit against Ampio Pharmaceuticals, Inc.

Investors who lost Money with shares of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) should contact the Shareholders Foundation in connection with the Lawsuit against Ampio Pharmaceuticals, Inc.

November 29, 2022

« 1 … 24 25 26 27 28 … 558 »